In previous studies, IRF8 activation demonstrated immunotherapeutic effect and human leukemia inhibition.[8, 34] The increased level of Chi3l3 was reasonable to explain by Chi3l3+ Ly6c+ polyfunctional monocyte attraction.[33] M2‐like macrophage and immune suppression‐relevant gene expressions showed decreased levels of IL‐10, Mgl‐1, and Mrc1 (CD206) in the T‐hNP/SnMP +DNR treatment group (Figure 7i). The gene discussed is IL10; the disease is leukemia.